July 28, 2015, New York — Remedy Pharmaceuticals, a company focused on the development and commercialization of CIRARA, a breakthrough drug treating acute central nervous system conditions such as stroke, today announced publication of a peer-reviewed paper that confirms administering CIRARA for pharmacological targeting of the Sur1-Trpm4 channel in human ischemic stroke to reduce blood-brain barrier disruption and cerebral edema is a promising therapeutic strategy.

Press Release